Group 1 - The company, Shuo Bei De (300322.SZ), has stated that it is not currently involved in the brain-computer interface business [1]

Group 1 - The three major indices experienced fluctuations and upward movement, with the pharmaceutical and biotechnology sector showing significant gains, particularly the medical device sector which rose by 1.14% [1] - Notable stocks included Tianzhihang-U, which surged over 15%, and Yingke Medical, which increased by more than 10%, along with several stocks reaching their daily limit [1] - The Medical Device ETF (159873) saw a substantial increase in trading volume, with over 26 million yuan in transactions and a turnover rate of 17%, marking it as the largest among its peers [1] Group 2 - The Medical Device ETF (159873) has recorded a net inflow of 26.5 million yuan over four consecutive days, leading its category with a net inflow rate exceeding 22% [1] - The ETF tracks the CSI All-Share Healthcare Equipment and Services Index, which has a significant focus on brain-computer interface concepts, accounting for over 19% of its composition [1] - The latest scale of the Medical Device ETF (159873) reached 152 million yuan, making it the largest in its category [1] Group 3 - The Tianhong Innovative Drug ETF (517380) is the only ETF in the market tracking the Hang Seng Hong Kong-Shenzhen Innovative Drug Selected 50 Index, covering the entire industry chain from preclinical research to commercialization [2] - Recent developments include a partnership between NVIDIA and Eli Lilly, where they plan to invest 1 billion USD over five years to establish a joint research lab in the San Francisco Bay Area, aimed at accelerating AI applications in the pharmaceutical industry [2] - The AI+Healthcare market is projected to exceed 100 billion USD, with significant advantages over traditional pharmaceutical research, creating a competitive edge through a closed-loop system of algorithms, data, and clinical scenarios [2]

Core Insights - The life and health sector is entering a new phase of "deep integration and rapid development" driven by globalization and technological revolution, with advanced technologies like artificial intelligence and brain-computer interfaces expanding the pathways for innovative drug and therapy translation [1] Group 1: Forum Highlights - The fifth Guanghua Forum held at Fudan University focused on "leading the frontier, cross-border integration, and empowering transformation," aiming to build a high-end platform for thought exchange and resource connection [1] - Experts emphasized the importance of translating scientific research into practical applications, with a focus on addressing clinical problems and ensuring that innovations are applicable and beneficial to society [2] Group 2: Research and Innovation - The integration of artificial intelligence and synthetic biology is reshaping the research paradigm in life sciences, with a push towards making biomedical research a quantitative science through big data and AI [2] - Challenges in the translation of synthetic biology technologies into the health industry include the need for a regulatory science-based approval system and effective collaboration between innovation and industry chains [2] Group 3: Institutional Development - The Guanghua Life and Health Association has become a crucial hub linking academia, industry, and investment, with over 14 member units and a network of more than 6,000 alumni [3] - Future initiatives will focus on project result showcases and facilitating connections between early-stage innovation projects and industry [3] Group 4: Collaborative Achievements - A cooperation agreement was signed between the Macau Translational Medicine Center and Fudan University Pudong Hospital to establish a research institute focused on micro-nano sensing technology, microfluidics, and organ chips [4]

Group 1: Industry Development - Suggestions for the transformation and upgrading of traditional industries, focusing on future industries such as quantum technology, biomanufacturing, brain-computer interfaces, embodied intelligence, and 6G communication [2] - Discussion on the shortcomings in institutional supply for technological innovation and the integration of education and technology talent development [2] Group 2: Consumption and Investment - Exploration of new consumption scenarios and services, with a focus on enhancing quality services in elderly care, childcare, and housekeeping [4] - Strategies to better stimulate private investment and the concept of "investing in people" [5] Group 3: Business Environment - Recommendations for better supporting the development of small and medium-sized enterprises and individual businesses, including clearing corporate debts and addressing issues of internal competition and low-price competition [6] Group 4: Economic and Financial Policies - Suggestions for fiscal and monetary policies to promote the healthy development of stock, bond, and foreign exchange markets [8] Group 5: Foreign Trade and Investment - Policies to support enterprises going global, including the development of free trade pilot zones, internationalization of the Renminbi, and cross-border e-commerce [10][11] Group 6: Rural Revitalization - Policies to support income growth for rural residents and improvements in housing, education, healthcare, and employment for those moving from rural to urban areas [12] Group 7: Employment and Income Distribution - Recommendations for improving the income distribution system, including adjustments to the minimum wage standard and measures for wealth accumulation and redistribution [17][18] - Discussion on policies and services to support flexible employment, migrant workers, and new employment forms [21] Group 8: Education and Social Security - Insights on children's enrollment and educational pathways, as well as suggestions for enhancing vocational and higher education [20] - Recommendations for social security coverage for flexible workers, elderly individuals, and vulnerable groups [21] Group 9: Housing and Healthcare - Suggestions for stabilizing the real estate market, optimizing housing supply, and addressing housing loan rates and public fund withdrawals [23][24] - Recommendations for improving the medical security system, including drug procurement and tiered diagnosis and treatment [24] Group 10: Green Development - Experiences with green and low-carbon living, along with suggestions for pollution prevention and ecosystem optimization [26]

Core Viewpoint - BrainCo has secretly submitted a listing application to the Hong Kong Stock Exchange, aiming to become the first company in the global brain-computer interface (BCI) sector to enter the public capital market [1][10]. Technology Choice - Founded by Harvard dropout Han Bicheng in 2015, BrainCo chose a non-invasive BCI technology route, contrasting with Neuralink's invasive approach [2][12]. - BrainCo's technology collects brain signals through super sensors without surgical implantation, focusing on practical applications and scalability [2][12]. - The company has achieved significant milestones, including enabling amputees to control prosthetic limbs with their thoughts, addressing a market of 24 million disabled individuals in China [12][14]. Commercial Breakthrough - BrainCo's business strategy is pragmatic, starting with clear medical needs and expanding into consumer applications [4][14]. - The company has seen a substantial increase in sales, with 2024 quarterly sales projected to be four to five times that of 2023 [4][14]. - BrainCo's products include smart prosthetic hands and attention training systems, creating a dual-driven model of "medical rehabilitation + consumer applications" [4][14]. Capital Competition - The BCI industry is on the verge of explosive growth, with Morgan Stanley predicting a $400 billion market in the U.S. by 2045 [15]. - BrainCo has raised approximately 2 billion RMB, marking the second-largest financing record in the global BCI sector after Neuralink [15]. - The company’s decision to list in Hong Kong aligns with the trend of Chinese companies returning to the market and aims to enhance its global influence [15]. Industry Resonance - The news of BrainCo's listing application has triggered a positive response in the capital market, with related stocks rising significantly [16]. - BrainCo's listing is seen as a critical indicator of the BCI industry's development, contrasting with Neuralink's focus on disruptive innovation [16]. - The market reflects differing valuation perspectives, with investors weighing the commercial viability of BrainCo against the speculative nature of Neuralink's technology [16].

Market Overview - The three major indices collectively rebounded on January 14, with the Shanghai Composite Index rising by 1.2%, the Shenzhen Component Index by 1.98%, and the ChiNext Index by 2.24%. Over 4,700 stocks in the market rose, with more than 100 stocks hitting the daily limit. The trading volume in the Shanghai and Shenzhen markets reached 2.22 trillion yuan, a decrease of 215.5 billion yuan compared to the previous trading day [1]. Sector Performance AI Applications - The AI application sector continued to strengthen, with stocks like Zhejiang Wenlian rising for three consecutive days, and Shiji Information hitting the daily limit. Other notable performers included Guangyun Technology and Zhidema, both rising over 10%. This surge follows Google's announcement of partnerships with major retailers and the launch of an open-source AI protocol for e-commerce [2]. Nonferrous Metals - The nonferrous metals sector experienced a rally, particularly in small and precious metals. Xianglu Tungsten Industry hit the daily limit, while Huaxi Nonferrous, Xingye Silver, and Xiamen Tungsten Industry reached historical highs. The tungsten market has seen significant price increases, with tungsten powder prices exceeding 1.1 million yuan per ton [3]. Semiconductor Equipment - Semiconductor equipment stocks saw continued growth, particularly in the cleanroom segment. Stocks like Shenghui Integration and Yashang Integration hit the daily limit and reached historical highs. The demand for equipment is expected to rise due to increased capacity utilization in domestic wafer fabs and the AI-driven storage supercycle [4]. Quantum Technology - The quantum technology sector experienced fluctuations but ultimately rose, with stocks like Demai Chemical hitting the daily limit. The Ministry of Industry and Information Technology has indicated a focus on quantum technology and brain-computer interfaces during the 14th Five-Year Plan [5]. Institutional Insights Market Outlook - According to Everbright Securities, the recent market adjustment is primarily due to profit-taking, but the overall market sentiment remains optimistic. The indices are expected to undergo a period of consolidation, with structural trends likely to continue [6][7]. AI in Healthcare - CITIC Securities reports that AI in healthcare is set to accelerate the restructuring of the trillion-yuan pharmaceutical market. By 2026, the commercialization of AI in healthcare is expected to become more certain, with a focus on AI drug development and medical data circulation [8]. Brain-Computer Interface Technology - Galaxy Securities notes that brain-computer interface technology is transitioning from laboratory research to industrial production, with significant developments expected from companies like Neuralink. The industry is supported by various policies aimed at promoting commercialization and innovation [9]. Space Photovoltaics - Guojin Securities highlights that space photovoltaics will emerge as a leading sector in the new energy market by 2026, driven by its high value and market recognition. The recent cancellation of export tax rebates is expected to create a "window" for companies to adjust before the seasonal downturn [10].

Group 1 - The pharmaceutical and biotechnology industry is entering an Innovation 3.0 era, with China leading in innovative drug development across new targets, technologies, and diseases, particularly in ADC, bispecific antibodies, and small nucleic acids [1] - Recent positive clinical data for small nucleic acid drugs, including Arrowhead's ARO-INHBE and ARO-ALK7 early PoC data, has boosted market confidence in their use for weight maintenance, while Reborna's core pipeline FXI siRNA shows promising prospects for thrombotic diseases [1] - The domestic CRO sector is experiencing a clear turning point in demand, with orders increasing in both volume and price since 2025, benefiting from the overseas expansion of innovative drugs and a stabilization in financing, leading to accelerated new orders for multiple CROs [1] Group 2 - The AI+pharmaceutical sector is exploring new business models, with OpenAI launching the ChatGPT Health module, and domestic AI drug companies forming strategic partnerships with global pharmaceutical firms [1] - Significant advancements in brain-computer interface technology have been announced, with Neuralink set to begin mass production in 2026, supported by domestic policies that promote brain-computer interfaces as a new economic growth point [1] - The innovative drug industry chain continues to show upward momentum, with a focus on high-growth CDMO and recovering domestic CROs within the CXO sector [1] Group 3 - The medical device industry still holds potential on the demand side, with supply-side upgrades occurring, and under normalized centralized procurement, domestic manufacturers have room to exchange price for volume [1]

国际医学回复：您好，感谢您对公司的关注。公司旗下医疗机构依托先进的诊疗设备、技术优势和患者 资源，在脑机接口领域开展了相关课题研究，已积累一定病例样本，进行部分数据分析、文章撰写与学 术会议交流。谢谢！ 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，国际医学(000516)01月13日在投资者关系平台上答复投资者关心的问题。 投资者提问：9月11日董秘在互动平台上曾回复说：公司旗下医疗机构引进脑机接口结合外骨骼机器人 或功能性电刺激等相关康复设备的康复训练系统，开展了脑深部电刺激手术、嵴髓神经电刺激手术、迷 走神经电刺激手术等相关手术，并与相关院校及科研单位开展了脑机接口方面的研究。请问：请详细介 绍脑机接口方面的研究和临床实验。谢谢 ...

Market Overview - The A-share market experienced a collective rebound with the Shanghai Composite Index rising by 1.2% to 4188.24 points, the Shenzhen Component Index increasing by 1.98% to 14449.57 points, and the ChiNext Index climbing by 2.24% to 3396.35 points, while the STAR Market 50 Index surged by 3.71% to 1524.03 points [1] - The total trading volume in the Shanghai and Shenzhen markets reached 2.22 trillion yuan, a decrease of 215.5 billion yuan compared to the previous trading day [1] - Over 4700 stocks in the market saw gains, with more than 100 stocks hitting the daily limit [1] Key Sectors AI Applications - The AI application sector continued to strengthen, with stocks like Zhwen Interactive rising for three consecutive days and Shiji Information hitting the daily limit [2] - Google announced partnerships with major global retailers to open-source AI protocols for e-commerce, indicating a broad development space for AI commercialization [2] Nonferrous Metals - The nonferrous metals sector saw a volatile rise, particularly in small and precious metals, with stocks like Xianglu Tungsten and Huaxi Nonferrous hitting daily limits [3] - Tungsten prices have surged, with tungsten powder exceeding 1.1 million yuan per ton and tungsten concentrate reaching 464,000 yuan per standard ton, both setting historical highs [3] Semiconductor Equipment - Semiconductor equipment stocks continued to rise, led by cleanroom-related companies, with Shenghui Integration and Yaxiang Integration hitting daily limits and reaching historical highs [4] - The domestic wafer fabrication capacity utilization rate is recovering, and there is a strong willingness to expand production, driven by AI-related demand [4] Quantum Technology - The quantum technology sector experienced fluctuations, with stocks like Demai Chemical hitting daily limits and Keda Guokuan rising over 10% [5] - The Ministry of Industry and Information Technology emphasized a focus on quantum technology and brain-computer interfaces during the 14th Five-Year Plan [5] Institutional Insights - Everbright Securities indicated that the market may undergo a period of adjustment, but structural trends are expected to continue, with a shift from high-performing sectors like commercial aerospace to relatively lower-performing sectors [6] - CITIC Securities highlighted that AI in healthcare is set to accelerate the restructuring of the trillion-yuan pharmaceutical market, with a clearer payment structure expected by 2026 [7] - Guojin Securities projected that space photovoltaics will emerge as a leading sector in the new energy market by 2026, with significant market recognition and ongoing investment opportunities [8]

Core Viewpoint - The AI healthcare sector is experiencing significant growth, with both A-shares and Hong Kong stocks showing strong performance, particularly in AI medical ETFs and related stocks [1][2][3] Group 1: A-share Market Performance - The largest medical ETF in the A-share market (512170) surged by 3%, reaching a near three-month high, with active trading exceeding 1 billion CNY within the first hour of trading [1] - Key stocks such as Meiyuan Health and Weining Health saw substantial gains, with Meiyuan Health achieving a four-day consecutive rise and Weining Health spiking by 14% at one point [1] Group 2: Hong Kong Market Performance - The Hong Kong medical sector continues to strengthen, with the Hong Kong Stock Connect medical theme index rising consistently since the beginning of the year, led by Alibaba Health, which increased by nearly 10% [2] - The newly listed Hong Kong Stock Connect medical ETF (159137) has seen significant gains, with a trading volume exceeding 110 million CNY and a peak increase of nearly 3% within three days of its launch [2] Group 3: AI Healthcare Developments - Recent collaborations in the AI healthcare field include a partnership between NVIDIA and Eli Lilly to invest 1 billion USD over five years in an AI drug development lab in Silicon Valley [3] - In China, Tsinghua University's team has developed an AI-driven high-throughput drug virtual screening platform, DrugCLIP, with research results published in the journal Science [3] - The penetration rate of AI healthcare applications is rapidly increasing, with Ant Group's AI assistant, Antifufu, surpassing 30 million monthly active users, and OpenAI's ChatGPT Health reaching over 40 million daily users globally [3] Group 4: Brain-Computer Interface Developments - Elon Musk announced that Neuralink's brain-computer interface products are set to enter mass production by 2026, with nearly automated surgical procedures [3] - Strong Brain Technology, a leading domestic company in the brain-computer interface sector, has submitted an IPO application to the Hong Kong Stock Exchange [3] - The Ministry of Industry and Information Technology in China has indicated a focus on quantum technology and brain-computer interfaces during the 14th Five-Year Plan, emphasizing technological breakthroughs and enterprise cultivation [3]